Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pandemic ‘Roadmap’ Will Show How To Develop New Vaccines in 100 Days

AMR, Clinical Trials & Digital Health Also Discussed At Oxford G7 Event

Executive Summary

The pharmaceutical industry is a key player in a new partnership that aims to bring the public and private sectors together to address future complex health threats.

You may also be interested in...



SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?

Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. 

 

Coronavirus Notebook: G7 Agree On ‘Clinical Trial Charter’, Regulators Focus On Real World Data

The European Medicines Agency has issued advice on managing thrombosis with thrombocytopenia syndrome (TTS) in people vaccinated with adenovirus vaccines, and Brazil has OKd the import of Sputnik V and Covaxin, albeit with numerous strings attached.

UK Gathers Global Leaders For Pandemic Preparedness Project

New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel